Where to start

OxyRevo

OxyRevo Space60 Hard Sitting Hyperbaric Chamber

Built-In Audio SystemStainless Steel ConstructionOngoing US-Based Phone Support

$36,549

View model ›

SUMMIT TO SEA

Summit to Sea 60″ Grand Dive Pro Plus Hyperbaric Chamber

Quality Inspected Before ShippingOngoing US-Based Phone Support

$21,995

View model ›

What Long COVID Actually Does to the Body

Long COVID is not simply tiredness that lingers after a virus clears. For a significant proportion of people who contract COVID-19, the post-acute phase brings a constellation of symptoms that persist for months or years: crushing fatigue, cognitive fog, exercise intolerance, disrupted sleep, and a kind of generalised inflammation that standard blood panels often fail to catch.

The underlying mechanisms researchers have identified include microclotting in small blood vessels, mitochondrial dysfunction, persistent neuroinflammation, and a dysregulated immune response that keeps firing long after the initial infection resolves. Oxygen delivery to tissues becomes compromised not because the lungs are failing in an obvious way, but because the microcirculation is damaged. That distinction matters enormously when you are trying to understand why some people with normal oxygen saturation readings still feel profoundly unwell.

Myalgic encephalomyelitis and chronic fatigue syndrome (ME/CFS), which predates the pandemic by decades, shares much of this pathology. Researchers studying both conditions have found similar patterns of reduced cerebral blood flow, oxidative stress, and impaired cellular energy production. The overlap is substantial enough that many clinicians now treat post-COVID fatigue and ME/CFS as expressions of the same underlying problem, which is why protocols developed for one tend to be studied in the context of the other.

How Hyperbaric Oxygen Therapy Addresses the Root Problems

A hyperbaric chamber for chronic fatigue works on a straightforward physical principle: when the pressure inside the chamber rises above atmospheric normal, your blood and plasma carry significantly more dissolved oxygen than they do at sea level. Under typical conditions, only haemoglobin transports oxygen. Under pressure, oxygen dissolves directly into plasma, cerebrospinal fluid, and interstitial fluid, reaching tissues that compromised microcirculation can no longer adequately supply through the usual route.

That extra oxygen does several things relevant to Long COVID and chronic fatigue. It supports mitochondrial function, giving cells the substrate they need to produce ATP more efficiently. It has well-documented anti-inflammatory effects, helping to dampen the cytokine activity that keeps post-viral patients in a state of low-grade systemic inflammation. It also promotes angiogenesis, the growth of new blood vessels, and supports neuroplasticity by stimulating brain-derived neurotrophic factor. The research on HBOT for healing and tissue repair is extensive, and these mechanisms translate directly to the symptoms that define Long COVID.

There is also a practical argument about the blood-brain barrier. Neuroinflammation is one of the more distressing features of Long COVID, producing the cognitive impairment patients often describe as brain fog. Hyperbaric oxygen appears to reduce neuroinflammation by improving oxygen availability to brain tissue and suppressing microglial activation. Studies examining cerebral blood flow in Long COVID patients undergoing HBOT have documented measurable improvements in perfusion alongside reported improvements in cognition and fatigue scores.

What the Research Actually Shows

The most cited clinical work on this specific application comes from a Tel Aviv University trial published in 2022, which enrolled Long COVID patients with persistent cognitive and fatigue symptoms. Participants received 40 sessions of hyperbaric oxygen therapy over two months, and the results included significant improvements in cognitive function, energy levels, sleep quality, and pain measures, alongside measurable changes in brain imaging and microstructural data. This was a randomised controlled trial with a sham control arm, which puts it several rungs above the anecdotal evidence that saturates this space.

Earlier research on ME/CFS, predating the pandemic, found that HBOT improved functional capacity and reduced fatigue in patients who had failed to improve with conventional management. The effect sizes were modest in some trials and more pronounced in others, which likely reflects differences in protocol, pressure, and patient selection rather than inconsistency in the underlying biology.

One nuance worth understanding: the pressure used in these trials typically falls in the 1.5 to 2.0 ATA range, not the mild 1.3 ATA used in most portable soft-shell chambers. This does not make mild HBOT useless, but it does mean the evidence base for higher-pressure protocols is currently stronger. Anyone comparing research findings to their own setup at home should hold that distinction clearly.

Pressure Levels and Protocol Decisions

The protocol question is one of the most practically important ones for anyone considering a home setup, and it does not have a single clean answer. Clinical HBOT centres typically run protocols of 40 sessions, each lasting 60 to 90 minutes, at pressures between 1.5 and 2.0 ATA. That structure comes from the published trials. At home, the variables you control are pressure ceiling, session length, session frequency, and whether you are breathing concentrated oxygen through a mask or simply breathing air inside a pressurised chamber.

Hard-shell chambers designed for home use, like the OxyRevo Quest36 and Quest30, can operate at pressures up to 2.0 ATA and include integrated oxygen concentrators delivering 90 to 97% oxygen. That combination puts home users within reach of the clinical parameters that produced the strongest research outcomes. The Quest36 accommodates one adult or an adult with a child and includes dual control panels, safety sensors, and cooling systems, making independent daily sessions genuinely practical. The Quest30, at roughly 89 inches long with a 30-inch diameter, is designed for lying-down sessions and brings the same pressure range in a more compact footprint.

Soft-shell chambers top out around 1.3 to 1.5 ATA, which is meaningful pressure but below the thresholds used in the strongest clinical trials. They are considerably less expensive and easier to set up, and some users report real benefit at these pressures. The honest position is that the evidence for the 1.5 to 2.0 ATA range is currently more robust, and for someone managing a serious condition like Long COVID or ME/CFS, that gap matters when making a significant financial decision.

Choosing the Right Chamber for Chronic Fatigue Use

Fatigue patients have specific practical needs that go beyond pressure specs. Sessions are typically an hour or longer, which means comfort is not a luxury feature. Someone managing post-exertional malaise, one of the hallmarks of both Long COVID and ME/CFS, may struggle with confined, uncomfortable sessions. They may also need to enter and exit the chamber without much physical effort, and they may want to do sessions alone without requiring a second person to operate the controls externally.

The OxyRevo Space60 addresses several of these concerns. It is a seated hard-shell chamber that includes a premium folding recliner inside the chamber itself, with large transparent viewing windows on both sides to reduce feelings of confinement. At 200 cm in length and available in 1.5 to 1.6 ATA configurations with a ceiling of 2.0 ATA, it is designed for independent operation, meaning users can control the chamber from inside without needing continuous external assistance. Optional add-ons include integrated red light therapy and near-infrared systems, which some Long COVID researchers have examined as complementary approaches to mitochondrial support.

For those who prefer to lie down during sessions, the Quest30 and Quest36 are both hard-shell options with full pressure range capability. The Quest36 is wider and can accommodate an adult with a child, which matters for families where a parent is the primary patient. Both include built-in cooling, sterilisation systems, and internal LED lighting. The sitting versus lying distinction mostly comes down to personal preference and how you respond to extended horizontal rest, though some users with breathing difficulties find a slightly inclined or seated position more comfortable.

Budget also shapes this decision considerably. A full hard-shell unit with oxygen concentrator represents a substantial outlay, and it is worth comparing that against the cost of running clinical sessions, which in the United States often run between $150 and $350 per session out of pocket. Forty sessions at a clinic adds up to a number that overlaps meaningfully with the purchase price of a home unit. Anyone planning a sustained protocol, rather than a brief trial, should run that calculation. You can browse the full range of hyperbaric chambers to compare configurations and pressure ratings side by side.

Home HBOT Chamber Comparison

The table below covers the units most relevant to a home chronic fatigue protocol, drawn from the range PPW carries. Pressure range and oxygen delivery method are the two most clinically significant variables for this use case.

Model	Type	Max Pressure	Oxygen System	Price
OxyRevo Quest36	Hard shell, lying	2.0 ATA	Integrated concentrator, 90–97% O2	$23,799
OxyRevo Quest30	Hard shell, lying	2.0 ATA	Integrated concentrator, 90–97% O2	$21,249
OxyRevo Apex32	Portable, lying	1.5 ATA	Not published	$8,499
OxyRevo Forward90	Portable, sitting	1.5 ATA	Not published	$9,199
OxyRevo Elite32	Portable, lying	1.4 ATA	10L concentrator, 90–97% O2	$7,499
Newtowne C4-40	Soft shell, lying	1.3 ATA	Oxygen hookup compatible	$8,995

The gap between 1.3 ATA and 2.0 ATA is more than a number on a spec sheet. At 1.3 ATA, plasma oxygen levels rise meaningfully above normal but remain well below the levels achievable at 1.5 to 2.0 ATA. For general wellness use or mild recovery, the lower pressure models are defensible. For a dedicated Long COVID or chronic fatigue protocol modelled on clinical research, the hard-shell units with full pressure range offer the closest approximation to studied conditions.

Pacing HBOT Around Post-Exertional Malaise

Post-exertional malaise (PEM) is the phenomenon where physical or cognitive exertion triggers a significant worsening of symptoms, sometimes delayed by 12 to 48 hours. It is the defining feature of ME/CFS and is common in Long COVID. It also creates a real complication for any therapy that involves the body doing work, even passive work like adaptation to pressure changes.

Most clinicians experienced with both HBOT and PEM recommend starting with shorter sessions at lower pressure and increasing gradually. Beginning at 1.3 to 1.4 ATA for 30 to 45 minutes, then extending session length and incrementally raising pressure over several weeks, gives the body time to adapt without triggering a crash. Some patients report feeling fatigue or a mild headache in the first few sessions, which usually resolves. If symptoms worsen meaningfully after sessions rather than stabilising, that is a signal to reduce the pressure or duration and progress more slowly.

The independence factor matters here. Because PEM can strike unpredictably, having a chamber you can operate alone at home, adjusting in real time without relying on a clinic appointment or an assistant, is a genuine clinical advantage. Chambers like the OxyRevo Quest30 and Quest36 include both internal and external control panels precisely because users may need to adjust or exit without help. That kind of design detail is worth weighing alongside the pressure specs.

Complementary Approaches Worth Considering

HBOT rarely works in isolation for this population. The research on Long COVID generally finds the best outcomes when oxygen therapy is combined with other supportive interventions. Pacing strategies, nutritional support targeting mitochondrial function (particularly B vitamins, CoQ10, and magnesium), and low-intensity movement within individual tolerance all appear to complement what hyperbaric sessions do at the cellular level.

Red light therapy is one of the more interesting adjuncts, and it operates through partially overlapping mechanisms: photobiomodulation stimulates cytochrome c oxidase in the mitochondrial electron transport chain, effectively improving the same energy production pathways that HBOT supports through increased oxygen availability. The two approaches are not redundant, they work on different points in the same system, which is why some practitioners use them together. The OxyRevo Space60 can be configured with integrated red light and near-infrared therapy systems, which removes the logistical friction of running two separate devices. For those exploring red light therapy devices independently, they can be used in sequence with hyperbaric sessions rather than simultaneously.

Sleep quality is another area where HBOT patients often report early improvement, and this matters because poor sleep dramatically worsens fatigue and cognitive impairment in Long COVID. The anti-inflammatory and neurological effects of regular sessions appear to normalise sleep architecture in some patients, which then creates a positive loop: better sleep supports recovery, which reduces the burden on the sessions themselves.

Safety Considerations and Who Should Not Use HBOT

Hyperbaric oxygen therapy has a well-established safety record across decades of clinical use, but it is not appropriate for everyone. The absolute contraindications include untreated pneumothorax and certain types of lung disease where trapped air could expand dangerously under pressure. Relative contraindications include uncontrolled seizure disorders, certain ear and sinus conditions that prevent pressure equalisation, and claustrophobia significant enough to make enclosed sessions unmanageable.

For most Long COVID and chronic fatigue patients without these specific contraindications, HBOT carries a low risk profile at the pressures available in home units. The most common side effects are ear pressure discomfort during pressurisation (managed by yawning, swallowing, or the Valsalva manoeuvre) and mild fatigue in the first week of sessions. Oxygen toxicity, a serious concern at very high pressures and pure oxygen, is not a realistic risk at the 1.5 to 2.0 ATA range with the oxygen concentrations used in home systems.

It is also worth understanding that HBOT for Long COVID and chronic fatigue sits in a different regulatory category than HBOT for wound care or decompression sickness, which carry FDA clearance. Home hyperbaric use for these applications falls into the wellness and personal use category. That does not make it illegitimate, the research is real and growing, but it does mean you are making an informed personal decision rather than following a mandated medical protocol. Understanding that distinction makes for better decision-making.

Building a Sustainable Home Protocol

The most common mistake people make with HBOT for chronic fatigue is treating it like a short course of antibiotics: a fixed number of sessions, done, finished. The research suggests that meaningful improvement typically requires at least 20 to 40 sessions, and for a condition as persistent as Long COVID or ME/CFS, maintenance sessions following an initial intensive period may be what sustains the gains.

A reasonable starting framework for someone with a hard-shell home unit looks like this: three to four sessions per week for the first month, each lasting 60 minutes at a pressure the body tolerates comfortably (starting lower and progressing toward the unit's rated maximum). If that is well tolerated and producing improvement, maintain that frequency for a second month. After two months, assess against your baseline measures and decide whether daily sessions, a reduced maintenance schedule, or a further intensive block is appropriate.

Logging sessions consistently helps. Note the pressure, duration, how you felt entering the session, and how you feel in the hours after. Long COVID symptoms are notoriously variable, and without a log it becomes very difficult to separate genuine protocol effects from day-to-day fluctuation. Some users also find that tracking cognitive function, not just fatigue, gives a clearer picture of progress, since cognitive improvements sometimes appear before energy levels shift. The broader physiological mechanisms behind HBOT are worth understanding before you start, because knowing what you are working toward helps interpret what you are experiencing session to session.

Chronic fatigue conditions are slow to respond and slow to relapse. That cuts both ways: changes take time to appear, but improvements, once established, tend to be durable. HBOT fits that timeline reasonably well. It is not a treatment that produces dramatic overnight results, but the accumulating evidence from Long COVID trials suggests that for many patients, consistent sessions over months produce functional improvements that other interventions have not. For those considering the clinical literature on HBOT's effects on inflammation, the mechanisms relevant to Long COVID are the same ones studied in wound healing and post-surgical recovery, applied to a different tissue target.

The rise in Long COVID has pushed hyperbaric oxygen therapy into mainstream wellness conversations in a way that would have seemed unlikely five years ago. The underlying science is not new, but the application to post-viral fatigue syndromes has given researchers a sharper lens through which to examine what these chambers actually do at the cellular and neurological level. That research is ongoing, the protocols are being refined, and the home equipment available today puts clinical-grade pressure parameters within reach of people who want to run a sustained protocol on their own terms. The comparison between soft-shell and hard-shell chambers is a natural starting point for understanding where the key specification differences lie, and how those differences map onto the therapeutic parameters that matter most for this use case.

More hyperbaric chambers worth a look

OxyRevo

OxyRevo Quest36 1.5 to 2.0 ATA Hard Hyperbaric Chamber

Stainless Steel Construction2.0 ATA PressureOngoing US-Based Phone Support

$23,799

View model ›

OxyRevo

OxyRevo Quest30 1.5 to 2.0 ATA Hard Hyperbaric Chamber

Stainless Steel ConstructionActive Cooling SystemOngoing US-Based Phone Support

$21,249

View model ›

Frequently asked questions